SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$2.91−0.29 (-9.06%)
Close on Nov 19, 2026Market cap $264.77MP/E –Yield –
SAB Biotherapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
SAB Biotherapeutics's revenue for the twelve months ending Dec 31, 2024 was $1.32M, down 40.9% year over year. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $60.88M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $1.32M | -40.9% |
| FY2023 | Dec 31, 2023 | $2.24M | -90.6% |
| FY2022 | Dec 31, 2022 | $23.90M | -60.7% |
| FY2021 | Dec 31, 2021 | $60.88M | +10.2% |
| FY2020 | Dec 31, 2020 | $55.24M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $114.70K | -62.4% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $263.14K | +207.7% |
| Q1 FY2024 | Mar 31, 2024 | $944.58K | +62.5% |
| Q4 FY2023 | Dec 31, 2023 | $305.01K | -85.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.27M | -64.7% |
| Q2 FY2023 | Jun 30, 2023 | $85.52K | -98.7% |
| Q1 FY2023 | Mar 31, 2023 | $581.10K | -95.1% |
| Q4 FY2022 | Dec 31, 2022 | $2.16M | -80.5% |
| Q3 FY2022 | Sep 30, 2022 | $3.59M | -75.5% |
| Q2 FY2022 | Jun 30, 2022 | $6.35M | -65.1% |
| Q1 FY2022 | Mar 31, 2022 | $11.80M | -30.3% |
| Q4 FY2021 | Dec 31, 2021 | $11.06M | – |
| Q3 FY2021 | Sep 30, 2021 | $14.68M | – |
| Q2 FY2021 | Jun 30, 2021 | $18.21M | – |
| Q1 FY2021 | Mar 31, 2021 | $16.93M | – |
See a number that looks wrong?